Category Archives: Global

Arise Sir Andrew (Witty)

Big Pharma received a nod in the UK’s New Year’s Honours List this week when a knighthood was duly bestowed upon GSK’s Andrew Witty — making him ‘Sir Andrew’ to you and me. For once, though, receiving such an honor did not exactly place him in totally exalted company.
Also posted in Op-Ed, leadership | Tagged , , , | Leave a comment

Lilly's Decentralized Global Launch Strategy

Global headquarters may get the strategic ball rolling for a new drug launch, but Lilly’s affiliates are responsible for bringing home the bacon, according to a Lilly global brand director.
Also posted in Market Access, Strategy, leadership | Tagged , | Leave a comment

GSK's Andrew Witty: Further Concerns for Europe

GSK’s Andrew Witty underlined his growing concerns with the business climate in Europe with his comments to the UK’s High Pay Commission last week. The Commission, set up by left-wing pressure group Compass, reported on the ‘corrosive’ effects of ‘boardroom excess’ and called for greater transparency in the setting of executive pay. The pay of [...]
Also posted in Europe, People, pricing | Tagged , , , , , | Leave a comment

Tiered Pricing Not Always a Win-Win

Tiered pricing, or selling critical medicines to developing countries at a standardized discount price, can improve access in the short term, but arbitrary demographic groupings and misaligned incentives often stack the deck in favor of manufacturers, not patients.
Also posted in Corporate Responsibility, Emerging Markets, IP, Manufacturing, Market Access, R&D, Strategy, pricing | 2 Comments

The Seven-Billion Society: What's In It For Pharma?

On Monday, the world’s population hit the 7 billion mark, repeating a pattern of largely unrestrained growth that has endured for the last century: the world is now adding roughly one billion people every 12 years. The UN Population Fund (UNPF) estimates that, barring some unforeseen demographic or environmental/development shifts, the figure will reach just [...]
Also posted in Op-Ed, healthcare | Tagged , , , , | 1 Comment